US Patent

US9174982 — Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases

Method of Use · Assigned to Walter and Eliza Hall Institute of Medical Research · Expires 2030-05-26 · 4y remaining

Vulnerability score 68/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects compounds that inhibit anti-apoptotic Bcl-2 proteins and methods for treating diseases associated with these proteins.

USPTO Abstract

Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-2 proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic Bcl-2 protein.

Drugs covered by this patent

Venclexta (venetoclax) · AbbVie

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-2537`	—	Venclexta
`U-2323`	—	Venclexta
`U-2537`	—	Venclexta

Patent Metadata

Patent number: US9174982
Jurisdiction: US
Classification: Method of Use
Expires: 2030-05-26
Drug substance claim: No
Drug product claim: No
Assignee: Walter and Eliza Hall Institute of Medical Research
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.